Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2009-02-20
2011-10-04
Canella, Karen (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S016500, C514S019300, C514S019400, C514S019500, C514S021500
Reexamination Certificate
active
08030278
ABSTRACT:
Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.
REFERENCES:
patent: 5550110 (1996-08-01), Cody et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5811416 (1998-09-01), Chwalisz et al.
patent: 2002/0082285 (2002-06-01), Lebwohl
patent: 0655463 (1995-05-01), None
patent: 0815870 (1998-01-01), None
patent: 0950418 (1999-10-01), None
patent: 96/19233 (1996-06-01), None
patent: 00/67024 (2000-11-01), None
patent: 01/00198 (2001-01-01), None
patent: 01/91736 (2001-12-01), None
patent: 03/009805 (2003-02-01), None
patent: 03/045434 (2003-06-01), None
patent: 2004/037235 (2004-05-01), None
patent: 2006/091767 (2006-08-01), None
Wu-Wong et al (The Journal of Pharmacology and Experimental therapeutics, 2000, vol. 293, pp. 514-521).
Murata et al (British Journal of Pharmacology, Apr. 2001, vol. 132, pp. 1365-1373).
Battistini et al. “Endothelins: A Quantum Leap Forward”, Drug News & Perspectives, Aug. 1995, pp. 365-391, vol. 8, No. 6.
Bell et al. (International Journal of Cancer 1999; 80: 295-302).
Bell et al. “Tumor blood flow modification by endothelin-related peptides in the rat HSN fibrosarcoma”, British Journal of Cancer, copyright 1996, pp. S161-S163, Supp.27.
Bell et al. “A Comparative Study of Tumor Blood Flow Modification in two Rat Tumor Systems Using Endothelin-1 and Angiotensin II: Influence of Tumor Size on Angiotensin II Response”, copyright 1996, pp. 730-738, vol. 67, No. 5.
Bell et al. “Vascular Response of Tumor and Normal Tissues to Endothelin-1 following Antagonism of ETa and ETb Receptors in Anaesthetised Rats”, Int. J. Cancer, copyright 1997, pp. 283-289, vol. 73, No. 2Int. J. Cancer.
Bell et al. Modification of Blood Flow in the HSN Tumor and Normal Tissues of the Rat by the Endothelin ETb Receptor Agonist, IRL 1620, Int. J. Cancer, copyright 1999, pp. 295-302, vol. 80, No. 2.
Bhalla et al. “Potentiation of morphine analgesia by BQ123, an endothelin antagonist”, Peptides, copyright 2002, pp. 1837-1845 vol. 23.
Bhargava et al. Modification of Brain and Spinal Cord Dopamine D1 Receptors Labeled with [3H]SCH 23390 After Morphine Withdrawal from Tolerant and Physically Dependent Rats, The Journal of Pharmacology and Experimental Therapeutics, copyright 1990, pp. 901-907 vol. 252, No. 3.
Chaplin et al. “Modification of Tumor Blood Flow: Current Status and Future Directions”, Seminars in Radiation Oncology, Jul. 1998, pp. 151-163, vol. 8, No. 3.
Davar et al. “Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve”, NeuroReport, copyright 1998, pp. 2279-2283, vol. 9, No. 10.
Davenport et al. “Classification of endothelin receptors and antagonists in clinical development”, Clinical Science, copyright 2002, pp. 1S-3S, vol. 103, No. 48.
Del Bufalo et al. “Endothelin-1 acts as a survival factor in ovarian carcinoma cells”, Clinical Science, copyright 2002, pp. 302S-305S, vol. 103, No. 48.
Duggan et al. “Protection against aspirin-induced human gastric mucosal injury by bosentan, a new endothelin-1 receptor antagonist”, Aliment Pharmacol Ther, copyright 1999, pp. 631-635, vol. 13.
Eisenberger, “Chemotherapy in prostate cancer,” Crawford E.D. and Das, Current Genitourinary Cancer Surgery. XVII+699P. Lea and Febiger: Philadelphia, Pennsylvania, USA; London, England, UK. ILLUS, 1990, pp. 507-518.
Fabricio et al. “Essential role for endothelin ETb receptors in fever induced by LPS (E. coli) in rats”, British Journal of Pharmacology, copyright 1998, pp. 542-548, vol. 125.
Jarvis et al. “ABT-627, an endothelin ETa receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain”, European Journal of Pharmacology, copyright 2000, pp. 29-35, vol. 388.
Kikuchi et al.“Decreased ETb Receptor Expression in Human Metastatic Melanoma Cells”, Biochemical and Biophysical Research Communications, copyright 1996, pp. 734-739, vol. 219, No. 3.
Kroodsma et al. “Endothelinen:mogelijk een nieuw farmacologisch aangrijpingspunt bij hart-en vaatziekten, nierziekten en oncologische aandoeningen”, Nederlands Tijdschrift Voor Geneeskunde, copyright 1997, Sep. 20, pp. 1806-1810, vol. 141, No. 38.
Lahav et al. “An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo”, Proceedings of the National Academy of Sciences of USA, copyright Sep. 1999 pp. 11496-11500, vol. 96.
Matsumaru et al. “Bosentan, a novel synthetic mixed-type endothelin receptor antagonist, attenuates acute gastric mucosal lesions induced by indomethacin and HCI in the rat: Role of endogenous endothelin-1”, Journal of Gastroenterology, copyright 1997 pp. 164-170 vol. 32.
Rai et al. “Evidence for the involvement of ETb receptors in ET-1 induced changes in blood flow to the rat breast tumor”, Cancer Chemother Pharmacol, copyright Nov. 8, 2002, pp. 21-28, vol. 51.
Rai et al. “ETb receptor agonist, IRL 1620, does not affect paclitaxel plasma pharmacokinetics in breast tumor bearing rats”, Journal of Pharmacy and Pharmacology, copyright 2005, pp. 869-879, vol. 57, No. 76.
Rajeshkumar et al. “Endothelin B receptor agoinst, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats”, Breast Cancer Research and Treatment, copyright 2005, pp. 237-247, vol. 94, No. 3.
Rajeshkumar et al. “ET-1(8-21) Increases Blood Perfusion and Enhances Paclitaxel Delivery to the Tumor”, Proceeding of the Annual meeting of the American Association for Cancer Research, New York, NY, US, copyright 2005, p. 1349, vol. 96.
Rajeshkumar et al. “IRL-162, A Tumor Selective Vasodilator, Augments the Uptakeand Efficacy of Chemotherapeutic Agents in Prostate Tumor Rats,” Vo. 67, No. 7, May 2007, pp. 701-713.
Rowinsky M.D.,et al. “Paclitaxel (Taxol)”, Review Article The New England Journal of Medicine, Apr. 13, 1995, pp. 1004-1014, vol. 332.
Takita, “Effect of vasodilators in experimental solid tumor chemotherapy”, Journal of Experimental and Clinical Cancer Research 1983 Italy, copyright 1999, pp. 47-48, vol. 2, No. 1 (Database Embase (online) Elsevier Science Publishers, Amsterdam).
University of Illinois at Chicago: “List of Posters Presentations in 2004 AAPS Annual Meeting (Baltimore)”, www2.uic.edu/stud—orgs/prof/aaps/posters.htm, Online pp. 1-4.
Wu, Recent Discovery and Development of Endothelin Receptor Antagonists, Expert Opinion on Therapeutic Patents, copyright 2000 pp. 1653-1668 vol. 10, No. 11.
Gulati Anil
Lenaz Luigi
Reddy Guru
Board of Trustees University of Illinois
Canella Karen
Cullman Louis C.
K&L Gates LLP
Spectrum Pharmaceuticals Inc.
LandOfFree
Methods, compositions and articles of manufacture for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods, compositions and articles of manufacture for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods, compositions and articles of manufacture for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4283887